Development of a CRISPR screening platform for the oncology market

Preliminary clinical trials harnessing the immune system of cancer patients to combat disease have shown to have impressive efficacy. Immune cells
isolated from a patient are genetically altered to allow for improved detection of cancerous cells and subsequently re-introduced into the patient. Yet despite its promise, rapid and cost effective manufacturing of this therapy remains a barrier to widespread adoption. This collaboration will refine a lab-on-a-chip approach, allowing for automated liquid handling and optimization of experimental conditions specific to the genetic engineering of primary breast cancer cells at scale. Streamlining the process will reduce costs and allow for screening targets at scale, while automation will improve standardization and reproducibility.

Faculty Supervisor:

William Muller

Student:

Partner:

Dropgenie

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

McGill University

Program: